TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06182774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Dose determined at enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Dose determined at enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose determined at enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dose determined at enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose determined at enrollment
Study: NCT04446481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback will be tested in both groups of Vets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: Neurofeedback will be tested in both groups of Vets
Study: NCT06152809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Memory-like Natural Killer Cells
Description: Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Memory-like Natural Killer Cells
Description: Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
Study: NCT06163833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell low dosage-80*10^6 cells
Description: MSCs have to be administered at the dosage of 80\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell low dosage-160*10^6 cells
Description: MSCs have to be administered at the dosage of 160\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-storage solution
Description: Placebo has to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. It has to be diluted 1:2 in a saline solution for a total of 36mL.
Study: NCT05871879

Intervention type: DIAGNOSTIC_TEST
Intervention: The 5-item modified frailty index
Description: The mFI-5 contains five items, including hypertension, diabetes, congestive heart failure (CHF), chronic obstructive lung disease (COPD), and physical function status, with each item attributing 1 point. Patients with an mFI-5 score greater than or equal to 2 were considered frail, while those with an mFI-5 score of 0 or 1 were considered nonfrail.
Study: NCT04636749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium laser
Description: Vaginal laser therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Sham laser therapy
Study: NCT05021627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac autonomic nerve modification
Description: Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP\[LSGP\]), the leftinfer oposterior area(left inferior GP\[LIGP\]), the right superoanterior area (rightanterior GP\[RAGP\]), the right inferoposterior area(right inferior GP\[RIGP\]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation
Description: Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.
Study: NCT05515809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parasternal block
Description: Echo-guided loco-regional anesthesia by bilateral parasternal block in immediate preoperative.~The drug used is Ropivacaine 2mg/ml, 0.2%. Injection of 20ml per side, under ultrasound control, after general anaesthesia and before skin incision, and therefore before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard pain management
Description: Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
Study: NCT06152809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous (under the skin) injection per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous (under the skin) injection per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Selective inhibitor of BCL-2 protein, 10, 50, or 100 mg tablets, via orally per standard-of-care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Selective inhibitor of BCL-2 protein, 10, 50, or 100 mg tablets, via orally per standard-of-care.
Study: NCT04552756

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Seizure Diary
Description: The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline.~To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present.
Study: NCT04760847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: These subjects will will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day. See attached IF Quick Facts for details provided to the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intermittent fasting
Description: These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast
Study: NCT05714891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: Dose will be assigned at enrollment
Study: NCT05695183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IV SafeLock
Description: Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
Study: NCT06534151

Intervention type: DEVICE
Intervention: CRT implantation
Description: A CRT is a device (that looks like a pacemaker) that will be used to help the ventricles contract synchronously.
Study: NCT05018611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeSkills Mobile
Description: A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
Study: NCT05566301

Intervention type: DRUG
Intervention: Clopidogrel
Description: All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel

Intervention type: DRUG
Intervention: Ticagrelor
Description: All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
Study: NCT05406687

Intervention type: OTHER
Group type: OTHER
Intervention: Health Navigator Model
Description: The Health Navigator Model will be a longitudinal, person-centered and community-based intervention focused on addressing both primary and secondary cancer prevention, as well as reducing wider barriers to healthcare. Health Navigators (HNs) will be professionals who have a background in social care and an understanding of the local user population, and will be embedded in settings familiar and accessible to people experiencing homelessness. The primary aspects of the HN role will be to identify the health needs and barriers of users, promote cancer awareness and education, facilitate timely access to healthcare services and cancer screening, provide practical assistance, delivered through regular in-person meetings, and utilize wider stakeholders, including healthcare professionals, to deliver the intervention. A comprehensive training package will be delivered to the HNs, covering population specific knowledge, interpersonal skills, cancer education and local resources.
Study: NCT06291922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: See arm description.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: See arm description.
Study: NCT05233228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help materials (to support smoking cessation)
Description: The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help materials (to support smoking cessation)
Description: The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based automated treatment for smoking cessation
Description: The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 26-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
Study: NCT05697822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Phone and Cloud-based Electronic Contact and Recording System
Description: A mobile phone application has been developed which is intended to be used by pregnant women and their healthcare workers. A pregnant woman can get registered in this app and enter information and data related to their health and current pregnancy. Their health worker at their health post can access this information on their mobile phone too. The pregnant woman can also input her daily symptom on this app. She can also input and/or access information on examination and tests that have been carried out. If a concerning symptom or event has been entered by a user in the app, the health worker will be notified through this app. The health worker can also track the pregnant women under their care through this application. A cloud-based database of pregnant women will have the details of all the pregnant women in a given ward or rural municipality. Health coordinators in the municipality will be able to access the database for their municipality and track the pregnant women, if needed.
Study: NCT05430347

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy: TCbHPy
Description: Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy: TCbHP
Description: Pertuzumab combined with docetaxel, carboplatin and trastuzumab (TCbHP) for neoadjuvant therapy of HR+/HER2+ breast cancer
Study: NCT04301609

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
Study: NCT06270901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Planetary Health Diet
Description: Planetary Health Diet Meal with 62 g of protein primarily from plant origin
Study: NCT05584709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-6129
Description: Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).
Study: NCT05394727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle-free injection device, Then traditional insulin pen
Description: Patients first received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional insulin pen , Then Needle-free injection device
Description: Patients first received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks.
Study: NCT06270901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Planetary Health Diet
Description: Planetary Health Diet Meal with 36 g of protein primarily from plant origin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Western Diet
Description: Western Diet Meal with 62 g of protein primarily from animal origin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Western Diet
Description: Western Diet Meal with 36 g of protein primarily from animal origin
Study: NCT05827068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1011.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1011.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1012.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1012.1
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1010.2
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1010.3
Description: Sterile liquid for injection
Study: NCT06453980

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 1 session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 1 session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants will receive HD-tDCS at 3 milliAmp for 20 minutes, for 1 session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants will receive HD-tDCS at 3 milliAmp for 20 minutes, for 1 session.
Study: NCT05568992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI system of optical detection of advanced adenomas
Description: AI system of optical detection of advanced adenomas
Study: NCT05147636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extubation with PEEP
Description: No aspiration within the 3 minutes before extubation and extubation with 10cmH2O PEEP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Aspiration
Description: Aspiration during cuff deflation
Study: NCT04182490

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LMN-101
Description: VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo
Study: NCT06465849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dentin Etching time for 5 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 5 seconds in the etch-and-rinse application strategy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dentin Etching time for 5 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 5 seconds in the etch-and-rinse application strategy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scotchbond Universal Plus; 3M
Description: Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Scotchbond Universal Plus; 3M).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Plus; 3M
Description: Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Scotchbond Universal Plus; 3M).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gluma Universal Bond; Kulzer
Description: Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Gluma Universal Bond; Kulzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gluma Universal Bond; Kulzer
Description: Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Gluma Universal Bond; Kulzer).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dentin Etching time for 15 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 15 seconds in the etch-and-rinse application strategy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dentin Etching time for 15 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 15 seconds in the etch-and-rinse application strategy.
Study: NCT05797285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: human keratin graft
Description: The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: human keratin graft
Description: The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
Study: NCT06255223

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose Radiotherapy (HDRT)
Description: SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose Radiotherapy (LDRT)
Description: Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.
Study: NCT05947877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-pharmacological pain management strategies
Description: Non-pharmacological pain management strategies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-pharmacological pain management strategies
Description: Non-pharmacological pain management strategies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-pharmacological pain management strategies
Description: Non-pharmacological pain management strategies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-pharmacological pain management strategies
Description: Non-pharmacological pain management strategies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-pharmacological pain management strategies
Description: Non-pharmacological pain management strategies